Health-Related Quality of Life in patients with hepatitis C in double and triple therapy
Autor(a) principal: | |
---|---|
Data de Publicação: | 2015 |
Outros Autores: | , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Revista da Escola de Enfermagem da USP (Online) |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0080-62342015000600937 |
Resumo: | Abstract OBJECTIVE Comparing Health-Related Quality of Life (HRQoL) scores in patients with chronic hepatitis C undergoing double and triple antiviral therapy and analyzing possible factors related to HRQoL. METHOD HRQoL was assessed using the Short Form 36 and Chronic Liver Disease Questionnaire, which were applied at baseline and at weeks 4, 12 and 16 of treatment to 32 patients divided into two groups: double therapy with pegylated interferon (IFN-PEG) and ribavirin, and triple therapy with PEG-IFN, ribavirin and telaprevir. RESULTS The reduction of HRQoL was greater in patients receiving triple therapy compared to those treated with two drugs, the most critical time is at 12 weeks in both groups. After removal of telaprevir, the triple therapy group significantly improved their HRQoL scores. Anxiety and depression before treatment, employment status and race are significantly related to diminished HRQoL. CONCLUSION Patients undergoing double and triple therapy have diminished HRQoL indexes, but the addition of telaprevir chooses a more significant decrease. |
id |
USP-24_49559591df529983400271524c3bd366 |
---|---|
oai_identifier_str |
oai:scielo:S0080-62342015000600937 |
network_acronym_str |
USP-24 |
network_name_str |
Revista da Escola de Enfermagem da USP (Online) |
repository_id_str |
|
spelling |
Health-Related Quality of Life in patients with hepatitis C in double and triple therapyHepatitis CQuality of LifeCombined Modality TherapyRibavirinInterferonsProtease InhibitorsAbstract OBJECTIVE Comparing Health-Related Quality of Life (HRQoL) scores in patients with chronic hepatitis C undergoing double and triple antiviral therapy and analyzing possible factors related to HRQoL. METHOD HRQoL was assessed using the Short Form 36 and Chronic Liver Disease Questionnaire, which were applied at baseline and at weeks 4, 12 and 16 of treatment to 32 patients divided into two groups: double therapy with pegylated interferon (IFN-PEG) and ribavirin, and triple therapy with PEG-IFN, ribavirin and telaprevir. RESULTS The reduction of HRQoL was greater in patients receiving triple therapy compared to those treated with two drugs, the most critical time is at 12 weeks in both groups. After removal of telaprevir, the triple therapy group significantly improved their HRQoL scores. Anxiety and depression before treatment, employment status and race are significantly related to diminished HRQoL. CONCLUSION Patients undergoing double and triple therapy have diminished HRQoL indexes, but the addition of telaprevir chooses a more significant decrease.Universidade de São Paulo, Escola de Enfermagem2015-12-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0080-62342015000600937Revista da Escola de Enfermagem da USP v.49 n.6 2015reponame:Revista da Escola de Enfermagem da USP (Online)instname:Universidade de São Paulo (USP)instacron:USP10.1590/S0080-623420150000600009info:eu-repo/semantics/openAccessFagundes,Raíssa NevesFerreira,Lincoln Eduardo Villela Vieira de CastroPace,Fábio Heleno de Limaeng2015-12-08T00:00:00Zoai:scielo:S0080-62342015000600937Revistahttp://www.scielo.br/reeuspPUBhttps://old.scielo.br/oai/scielo-oai.php||nursingscholar@usp.br1980-220X0080-6234opendoar:2015-12-08T00:00Revista da Escola de Enfermagem da USP (Online) - Universidade de São Paulo (USP)false |
dc.title.none.fl_str_mv |
Health-Related Quality of Life in patients with hepatitis C in double and triple therapy |
title |
Health-Related Quality of Life in patients with hepatitis C in double and triple therapy |
spellingShingle |
Health-Related Quality of Life in patients with hepatitis C in double and triple therapy Fagundes,Raíssa Neves Hepatitis C Quality of Life Combined Modality Therapy Ribavirin Interferons Protease Inhibitors |
title_short |
Health-Related Quality of Life in patients with hepatitis C in double and triple therapy |
title_full |
Health-Related Quality of Life in patients with hepatitis C in double and triple therapy |
title_fullStr |
Health-Related Quality of Life in patients with hepatitis C in double and triple therapy |
title_full_unstemmed |
Health-Related Quality of Life in patients with hepatitis C in double and triple therapy |
title_sort |
Health-Related Quality of Life in patients with hepatitis C in double and triple therapy |
author |
Fagundes,Raíssa Neves |
author_facet |
Fagundes,Raíssa Neves Ferreira,Lincoln Eduardo Villela Vieira de Castro Pace,Fábio Heleno de Lima |
author_role |
author |
author2 |
Ferreira,Lincoln Eduardo Villela Vieira de Castro Pace,Fábio Heleno de Lima |
author2_role |
author author |
dc.contributor.author.fl_str_mv |
Fagundes,Raíssa Neves Ferreira,Lincoln Eduardo Villela Vieira de Castro Pace,Fábio Heleno de Lima |
dc.subject.por.fl_str_mv |
Hepatitis C Quality of Life Combined Modality Therapy Ribavirin Interferons Protease Inhibitors |
topic |
Hepatitis C Quality of Life Combined Modality Therapy Ribavirin Interferons Protease Inhibitors |
description |
Abstract OBJECTIVE Comparing Health-Related Quality of Life (HRQoL) scores in patients with chronic hepatitis C undergoing double and triple antiviral therapy and analyzing possible factors related to HRQoL. METHOD HRQoL was assessed using the Short Form 36 and Chronic Liver Disease Questionnaire, which were applied at baseline and at weeks 4, 12 and 16 of treatment to 32 patients divided into two groups: double therapy with pegylated interferon (IFN-PEG) and ribavirin, and triple therapy with PEG-IFN, ribavirin and telaprevir. RESULTS The reduction of HRQoL was greater in patients receiving triple therapy compared to those treated with two drugs, the most critical time is at 12 weeks in both groups. After removal of telaprevir, the triple therapy group significantly improved their HRQoL scores. Anxiety and depression before treatment, employment status and race are significantly related to diminished HRQoL. CONCLUSION Patients undergoing double and triple therapy have diminished HRQoL indexes, but the addition of telaprevir chooses a more significant decrease. |
publishDate |
2015 |
dc.date.none.fl_str_mv |
2015-12-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0080-62342015000600937 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0080-62342015000600937 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1590/S0080-623420150000600009 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Universidade de São Paulo, Escola de Enfermagem |
publisher.none.fl_str_mv |
Universidade de São Paulo, Escola de Enfermagem |
dc.source.none.fl_str_mv |
Revista da Escola de Enfermagem da USP v.49 n.6 2015 reponame:Revista da Escola de Enfermagem da USP (Online) instname:Universidade de São Paulo (USP) instacron:USP |
instname_str |
Universidade de São Paulo (USP) |
instacron_str |
USP |
institution |
USP |
reponame_str |
Revista da Escola de Enfermagem da USP (Online) |
collection |
Revista da Escola de Enfermagem da USP (Online) |
repository.name.fl_str_mv |
Revista da Escola de Enfermagem da USP (Online) - Universidade de São Paulo (USP) |
repository.mail.fl_str_mv |
||nursingscholar@usp.br |
_version_ |
1748936537789169664 |